DAW2020 on OSA Endotypic Traits

Enrolling by invitation · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Obstructive Sleep Apnea (OSA)

In brief

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of DAW2020 administered before sleep on OSA phenotype traits and OSA severity during sleep.

Key facts

Study ID
NCT04538755
Run by
Brigham and Women's Hospital
People needed
20
Starts
2020-11-15
Expected to finish
2026-12-15
Last updated by the study team
2026-07-15

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.